By Mariam Sunny and Bhanvi Satija Jan 28 (Reuters) - U.S. drugmaker Eli Lilly signed an agreement worth up to $1.12 billion ...

Eli Lilly and Company (NYSE:LLY) is included among the 12 Best Stocks to Buy for the Long Term. According to a report by ...

What if a cup of coffee could help treat cancer? Researchers at the Texas A&M Health Institute of Biosciences and Technology ...

Cellares is partnering with Stanford Medicine to automate gene-edited stem cell therapy for HIV and more than 19 rare diseases.

Gene-editing tools like CRISPR have unlocked new treatments for previously uncurable diseases. Now, researchers at the ...

Researchers developed a topical gene therapy that corrects disease-causing mutations in human skin models using lipid ...

Explore groundbreaking gene-editing therapy for kidney disease, offering hope to those with polycystic kidney disease.

REPROCELL today announced the commercial launch of StemEdit, its clinical gene editing services and new gene-edited iPSC product lines leveraging OpenCRISPR-1™, an AI-designed genome editing system ...

Eli Lilly is continuing a run of dealmaking to strengthen its genetic medicine offering by penning a pact with gene editing ...

Caffeine could act as an on-off switch for gene and cell therapies, giving doctors more precise control over powerful ...

On behalf of Lilly, Seamless will design and programme recombinases that can correct alterations in multiple genes involved ...

Australian scientists have used AI to design molecules that make gene editing technology safer, potentially revolutionising ...